Showing results (61-70 of 76) with videos related to

Sort By:
Pageof 8
International Seminars in Surgical Oncology : ISSO|February 7, 2006
Prognostic significance of pathological response after neoadjuvant chemotherapy or chemoradiation for locally advanced cervical carcinomaMyrna Candelaria, José Chanona-Vilchis, Lucely Cetina, et al.
Gaceta Medica De Mexico|June 24, 2016
[Initial surgical management of squamous carcinoma of the vulva]Israel Salazar-Báez, Jessica E Salazar-Campos, Alhely López-Arias, et al.
Medical Oncology (Northwood, London, England)|October 9, 2010
A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary resultsJaime Coronel, Lucely Cetina, Irlanda Pacheco, et al.
Expert Opinion on Investigational Drugs|March 10, 2017
Efficacy of hydralazine and valproate in cutaneous T-cell lymphoma, a phase II studyJose Ramiro Espinoza-Zamora, Juan Labardini-Méndez, Alejandro Sosa-Espinoza, et al.
Annals of Hematology|October 6, 2010
Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trialMyrna Candelaria, Aquileo Herrera, Juan Labardini, et al.
Cancer Cell International|February 2, 2006
Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell linesAlma Chavez-Blanco, Carlos Perez-Plasencia, Enrique Perez-Cardenas, et al.
Plos One|March 20, 2012
DNA methylation-independent reversion of gemcitabine resistance by hydralazine in cervical cancer cellsMyrna Candelaria, Erick de la Cruz-Hernandez, Lucia Taja-Chayeb, et al.
Molecular Cancer|July 9, 2005
Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I studyAlma Chavez-Blanco, Blanca Segura-Pacheco, Enrique Perez-Cardenas, et al.
Leukemia & Lymphoma|July 6, 2019
Rituximab biosimilar RTXM83 versus reference rituximab in combination with CHOP as first-line treatment for diffuse large B-cell lymphoma: a randomized, double-blind studyMyrna Candelaria, Derlis E González, Marcia Torresan Delamain, et al.
Expert Review of Anticancer Therapy|June 24, 2024
Multitargeted polypharmacotherapy for cancer treatment. theoretical concepts and proposalsAlfonso Duenas-Gonzalez, Aurora Gonzalez-Fierro, Leticia Bornstein-Quevedo, et al.
Pageof 8